Success Metrics

Clinical Success Rate
60.0%

Based on 3 completed trials

Completion Rate
60%(3/5)
Active Trials
0(0%)
Results Posted
33%(1 trials)
Terminated
2(29%)

Phase Distribution

Ph not_applicable
3
43%
Ph phase_1
1
14%
Ph phase_3
3
43%

Phase Distribution

1

Early Stage

0

Mid Stage

3

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
1(14.3%)
Phase 3Large-scale testing
3(42.9%)
N/ANon-phased studies
3(42.9%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(3)
Terminated(2)
Other(2)

Detailed Status

Completed3
Terminated2
unknown2

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
60.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (14.3%)
Phase 33 (42.9%)
N/A3 (42.9%)

Trials by Status

terminated229%
completed343%
unknown229%

Recent Activity

Clinical Trials (7)

Drug Details

Intervention Type
DRUG
Total Trials
7